



| |
|---|
| IN CASE OF EMERGENCY Emergency Phone: (614) 276-4000 |
|---|

Material Safety Data Sheet

| 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION | | |
|---|--|------------------|
| Common/Trade Name: Losartan Potassium and Hydrochlorothiazide Tablets | | |
| Chemical Name: 2-Butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt and Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide | | |
| Synonyms: None | | |
| Molecular Formula: C ₂₂ H ₂₂ ClKN ₆ O and C ₇ H ₈ ClN ₃ O ₄ S ₂ | | |
| Molecular Weight: 461.01 and 297.74 | | |
| CAS No: 124750-99-8 and 58-93-5 | | |
| Chemical Family: Angiotensin II receptor (type AT ₁) antagonist and a Diuretic | | |
| Product Use: Indicated for the treatment of hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. | | |
| Manufacturer's Name: Boehringer Ingelheim Roxane Inc. | | |
| Address: 1809 Wilson Road Columbus, Ohio 43228 | | |
| 2. COMPOSITION / INFORMATION ON INGREDIENTS | | |
| Composition | CAS# | Exposure Limit |
| Losartan Potassium (active ingredient) | 124750-99-8 | None established |
| Hydrochlorothiazide (active ingredient) | 58-93-5 | None established |
| <i>REFER to PHYSICIAN'S DESK REFERENCE for common components present as <1%</i> | | |
| 3. HAZARDS IDENTIFICATION | | |
| Emergency Overview | Physical State: Round, film-coated, biconvex, beveled-edge tablets or Round, biconvex, beveled-edge tablets The 50 mg/12.5 mg tablets are yellow and have "54 717" debossed on one side and are blank on the other. The 100 mg/12.5 mg tablets are white and have "54 931" debossed on one side and are blank on the other. The 100 mg/25 mg tablets are yellow and have "54 557" debossed on one side and are blank on the other. Odor: No data available WARNING! May be harmful if swallowed. Accidental ingestion of large amounts may be harmful. | |
| Primary Route(s) of Entry | Ingestion | |
| Potential Health Effects: | Inhalation: Not expected to be an inhalation hazard in final pharmaceutical form. Eye Contact: Not expected to be a hazard to the eye in final pharmaceutical form. Skin Contact: Not expected to be a hazard to the skin. Can cause hypersensitive reactions resulting in rash, redness, itching and inflammation. Ingestion: May be harmful if ingested. Ingestion may cause nausea, abdominal pain, chest pain, cough and dizziness. | |
| Toxicity Data: | See Section 11 | |

| | | |
|---|---|------------|
| Effects of Overexposure: | The potential for exposure is reduced in finished pharmaceutical form. Overexposure by ingestion may cause increased severity of adverse effects, dehydration, hypotension and rapid/increasing heart rate. | |
| Target Organs: | Blood, Cardiovascular System, Kidneys | |
| 4. FIRST AID MEASURES | | |
| Eye Exposure | Any material that contacts the eye should be washed out immediately with water. If easy to do, remove contact lenses if worn. Get medical attention if symptoms persist. | |
| Skin Exposure | Wash with soap and water. Get medical attention if symptoms occur. | |
| Ingestion | Call a physician or poison control center immediately. | |
| Inhalation | Should not pose a hazard in the final form. If breathing is difficult, move to fresh air. Get medical attention immediately. | |
| 5. FIRE AND EXPLOSION HAZARDS | | |
| Flammability | Lower: N/A | Upper: N/A |
| Flash Point | Not Applicable | |
| Extinguishing Media | Use water spray, dry chemical, carbon dioxide or material appropriate for fire in surrounding area | |
| Special Fire Fighting Procedures | Wear full protective clothing and self-contained breathing apparatus. | |
| Unusual Fire/Explosion Hazards | Not Applicable | |
| Hazardous Combustion Products | Carbon dioxide, carbon monoxide, oxides of nitrogen, oxides of potassium, oxides of sulfur, hydrogen chloride | |
| 6. ACCIDENTAL RELEASE INFORMATION | | |
| STEPS TO BE TAKEN IF SIGNIFICANT QUANTITIES OF PRODUCT IS SPILLED: Use appropriate personal protective equipment (see Section 8). Sweep up and containerize spill material in a compatible container. Dispose according to applicable regulations. Incineration of the waste at an approved facility is recommended. | | |
| 7. PRECAUTIONS FOR SAFE HANDLING AND USE | | |
| Precautions Handling Significant Quantities of Product: | Observe good industrial hygiene practices. | |
| Storage | Store at 20° to 25°C (68° to 77°F). Keep container closed tightly. Protect from light and moisture. Store away from foodstuffs. | |
| 8. CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT | | |
| Exposure Limits | None | |
| Engineering Controls | Not required when handling tablets or containers. Ventilation should be matched to conditions. | |
| Respiratory Protection | Not required when handling tablets or containers. NIOSH/MSHA approved respirators for protection should be used if respirators are found to be necessary. Ventilation should be matched to conditions. | |
| Personal Protection | Not required when handling tablets. If containers are compromised or exposure is likely wear: Goggles, Lab Coat, Gloves | |
| Recommended Facilities | Eye wash, washing facilities | |
| 9. PHYSICAL / CHEMICAL CHARACTERISTICS | | |

| | | | | | |
|------------|---|----------------|---------------|---------------------|---------------|
| Appearance | Round, yellow film-coated, biconvex, beveled-edge tablets or Round, white, biconvex, beveled-edge tablets | Melting point | Not available | Solubility in water | Not available |
| Odor | Not available | Boiling point | Not available | Specific Gravity | Not available |
| Taste | Not available | Vapor Pressure | Not available | Flashpoint | Not available |
| pH | Not available | Density | Not available | Flammability Limits | Not available |

10. STABILITY AND REACTIVITY DATA

| | |
|--------------------------|--|
| Stability | Stable |
| Incompatibility | None known |
| Hazardous Decomposition | Oxides of carbon, oxides of nitrogen, oxides of potassium, oxides of sulfur, hydrogen chloride |
| Conditions to Avoid | Excessive heat, light |
| Hazardous Polymerization | Will not occur. |

11. TOXICOLOGICAL INFORMATION**Acute Toxicity:****Active Ingredient:**

Hydrochlorothiazide: Oral LD50 (rat): 2750 mg/kg

Hydrochlorothiazide: Oral LD50 (mouse): 1175 mg/kg

Losartan Potassium is considered a possible teratogen and fetotoxin.

Carcinogenicity: Not listed as a carcinogen by NTP, IARC Monographs or OSHA.

12. ENVIRONMENTAL IMPACT INFORMATION

No information is currently available on the environmental impact of this product.

13. DISPOSAL INFORMATION

Waste Disposal Considerations: Dispose of material according to federal, state and local disposal regulations or company operating procedures. Disposal by incineration is recommended.

At home: Discard away from children's reach.

14. TRANSPORTATION INFORMATION

This product is not subject to the regulations for the safe transport of hazardous chemicals.

DOT: Not regulated

TDG: Not regulated

IATA: Not regulated

IMDG: Not regulated

15. REGULATORY INFORMATION

DEA: Losartan Potassium and Hydrochlorothiazide are not controlled substances.

FDA: Losartan Potassium and Hydrochlorothiazide are approved prescription medications.

Inventory Status: These materials are not listed on the US TSCA Inventory. Therefore, this product can only be used for TSCA exempt purposes such as R&D or drug use.

These materials are not listed on the DSL Inventory but are exempt.

| |
|---|
| 16. OTHER DATA |
| ABBREVIATIONS: N/A – not applicable |
| Prepared by: Boehringer Ingelheim Roxane, Inc. |
| References: <ol style="list-style-type: none">1. Losartan K-HCTZ Tablets, Package Insert, Boehringer Ingelheim Roxane, Inc. , Columbus, Ohio2. RTECS No. NI675100 – 2-Butyl-4-chloro-1-[p-(o-1 H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt3. RTECS No. DK9100000 - Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide4. Ariel Webinsight. Regulatory and ChemExpert Database.5. PDR – Physicians Desk Reference |
| Date: 04/14/2010 - New MSDS |
| SEE CURRENT PACKAGE INSERT FOR FURTHER INFORMATION |

The information provided is believed to be complete and accurate. If this product is combined with other materials, deteriorates or becomes contaminated, it may pose hazards not mentioned in this MSDS. It is the users' responsibility to use the information according to the application. Boehringer Ingelheim Roxane, Inc. assumes no responsibility or liability resulting from the use of this information.